Merck says 2026 earnings will take a hit due to its pending takeover of Cidara Therapeutics.

Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can ...

Merck (NYSE: MRK) stock rose 2% Friday morning after Deutsche Bank analyst James Shin upgraded the pharmaceutical giant from Hold to Buy, setting a price target of $150.00, up from $115.00.

Merck shares began peeling back in early 2024, mostly on concerns about looming patent expirations for its breadwinning drug. The trading crowd changed its collective mind a couple months ago, sending ...

Merck & Co. is no longer a deep-value patent cliff trade but a fairly valued defensive compounder. Read why I have downgraded ...

Merck & Co. Inc. stock reached a 52-week high, closing at $122.69. This milestone highlights a significant upward trend for the pharmaceutical giant, marking a notable recovery and growth over the ...

New KEYTRUDA indications are expected to preserve Merck's top line. Click here to read why MRK stock remains a great buy upon correction.

Shares of Merck & Co. Inc. MRK rose 1.82% to $121.93 Friday, on what proved to be an all-around great trading session for the ...

We recently published Wall Street Analysts Like These 10 Stocks. Merck & Co., Inc. (NYSE:MRK) is one of the stocks analysts were recently talking about. Bill Nygren, Oakmark Funds partner and CIO, ...

A top U.S. health official's call to split the measles-mumps-rubella (MMR) vaccine into separate shots sparked strong pushback from Merck & Co., Inc. (NYSE:MRK) and medical experts, who said such a ...